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Cystic fibrosis (CF) is the major genetic inherited diseasein the European Caucasian
population, with an average of 1 in 3000 living births in France. Prognostic depend
essentially on the lung impairments. While considerable attention therefore has
been paid over recent decades to prevent and treat bacterial respiratory infections,
we observed emergence of fungi colonization in CF respiratory tract. In particular,
Aspergillus fumigatus represents the most common causative agent colonizing the
airways of CF patients; it can be responsible for Allergic Bronchopulmonary
Aspergillosis (ABPA). Since
oral corticosteroids and itraconazole represent the mainstay of ABPA treatment,
long-term therapy may increase the risk of acquired resistance to azoles that is
mainly associated with amino acid substitutions in the CYP51A gene of A.
fumigatus.
Objective:
Because CF patients are chronically exposed to itraconazole, our study aimed to
evaluate the prevalence of azole resistance in isolates prospectively collected from
CF patients followed-up in seven French hospitals involved in our national
prospective study (“MucoFong” study − PHRC1902). To our knowledge, it is the
first multicenter study
focused on azole resistance of A. fumigatus in CF.
Methods:
A total of 87 isolates of A. fumigatus was collected in 85 patients. The MICs of azole
drugs were evaluated for each isolate using the E-test ® strips. Isolates were
characterized at the molecular level by targeting ITS, b-tubulin and MAT-A/a genes.
The cyp51A gene as well as its promoter was sequenced.
Results and Discussion:
A majority of isolates (88.1%) were found sensitive to itraconazole (MIC 2 mg/ml),
and 2 new mutations were identified and localized within 3-dimensional Cyp51A
protein model. To obtain insight into azole resistance of A. fumigatus, the results
are analyzed taking into account clinical data, itraconazole exposition, and the
potential correlation between the identified CYP5IA mutations and azole resistance
is discussed based on the Cyp51A protein homology model.
Notes
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